GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Asia Green Biotechnology Corp (XCNQ:ASIA) » Definitions » Total Liabilities

Asia Green Biotechnology (XCNQ:ASIA) Total Liabilities : C$0.53 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Asia Green Biotechnology Total Liabilities?

Asia Green Biotechnology's Total Liabilities for the quarter that ended in Dec. 2023 was C$0.53 Mil.

Asia Green Biotechnology's quarterly Total Liabilities increased from Jun. 2023 (C$0.38 Mil) to Sep. 2023 (C$0.40 Mil) and increased from Sep. 2023 (C$0.40 Mil) to Dec. 2023 (C$0.53 Mil).

Asia Green Biotechnology's annual Total Liabilities increased from Dec. 2021 (C$0.19 Mil) to Dec. 2022 (C$0.31 Mil) and increased from Dec. 2022 (C$0.31 Mil) to Dec. 2023 (C$0.53 Mil).


Asia Green Biotechnology Total Liabilities Historical Data

The historical data trend for Asia Green Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asia Green Biotechnology Total Liabilities Chart

Asia Green Biotechnology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 0.09 0.03 0.19 0.31 0.53

Asia Green Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.35 0.38 0.40 0.53

Asia Green Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Asia Green Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.527+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.53

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=0.065--0.462
=0.53

Asia Green Biotechnology's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.527+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.53

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=0.065--0.462
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asia Green Biotechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Asia Green Biotechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Asia Green Biotechnology (XCNQ:ASIA) Business Description

Traded in Other Exchanges
N/A
Address
707 - 7th Avenue SW, Suite 1150, Calgary, AB, CAN, T2P 3H6
Asia Green Biotechnology Corp is an early stage international agri-technology company focused on the development, evaluation, testing, application and, ultimately, supply to the market of proprietary organic hybridization technology and certain products derived from that technology. The core approach of the business is centred on the planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities. The company is developing varieties of hemp with superior growth and production characteristics in the various environments found in the licensed territories.
Executives
Johannes Kingma Senior Officer

Asia Green Biotechnology (XCNQ:ASIA) Headlines